Letter to the Editor: Efficacy and safety of the generic forms of sofosbuvir/ledipasvir in chronic hepatitis C virus adolescents in Upper Egypt

doi:10.4254/wjh.118661

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(3)

(0)

(14)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 118661
Published online Aug 27, 2026. doi: 10.4254/wjh.118661

Letter to the Editor: Efficacy and safety of the generic forms of sofosbuvir/ledipasvir in chronic hepatitis C virus adolescents in Upper Egypt

Nahed A Makhlouf

Nahed A Makhlouf, Department of Tropical Medicine and Gastroenterology, Medical Director of Liver Transplantation Program, Al-Rajhi Liver Hospital, Faculty of Medicine, Assiut University, Assiut 71515, Egypt

Author contributions: Makhlouf NA wrote the original draft, re-reviewed and edited the manuscript according to reviewer’s comments, and approved the final version of the manuscript.

Conflict-of-interest statement: Dr. Makhlouf has nothing to disclose.

Corresponding author: Nahed A Makhlouf, MD, Professor, Department of Tropical Medicine and Gastroenterology, Medical Director of Liver Transplantation Program, Al-Rajhi Liver Hospital, Faculty of Medicine, Assiut University, Kornish Al-Ibrahimeya Street, Assiut 71515, Egypt. nahedmak@yahoo.com

Received: January 21, 2026
Revised: January 28, 2026
Accepted: February 5, 2026
Published online: August 27, 2026
Processing time: 222 Days and 17.5 Hours

Abstract

Mogahed et al recently published a retrospective study in the World Journal of Hepatology, which assessed the safety and efficacy of the generic sofosbuvir (SOF)/ledipasvir (LED) in Egyptian hepatitis C virus (HCV)-infected children in comparison with the brand form. They concluded that, the use of generic SOF/LED in HCV infected children is safe and effective. Previous study in 2021 on chronic HCV in adolescents used the generic SOF/LED at Assiut, Upper Egypt. Sustained virologic response (SVR12) was 100% both in treatment naïve with or without haematological disorders and in non-responder to pegylated interferon/ribavirin. The treatment was well tolerated, with minimal side effects. We also support the use of the generic forms of SOF/LED in HCV infected children and adolescents in Egypt and other resource limited countries.

Keywords: Adolescents; Hepatitis C virus; Generic; Ledipasvir; Sofosbuvir; Treatment naïve; Treatment experienced; Egypt

Core Tip: Using brand forms of direct acting antivirals (DAAs) against hepatitis C virus (HCV) is limited in low- and middle-income countries. Generic forms of DAAs were widely used in adults. Few studies addressed this issue in children and adolescents in Egypt. We support the use of the generic forms of sofosbuvir/ledipasvir in HCV infected children and adolescents.